These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 24746164)
21. FGF2 as a potential prognostic biomarker for proneural glioma patients. Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081 [TBL] [Abstract][Full Text] [Related]
22. Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. Martinho O; Granja S; Jaraquemada T; Caeiro C; Miranda-Gonçalves V; Honavar M; Costa P; Damasceno M; Rosner MR; Lopes JM; Reis RM PLoS One; 2012; 7(1):e30769. PubMed ID: 22292035 [TBL] [Abstract][Full Text] [Related]
23. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780 [No Abstract] [Full Text] [Related]
24. Advances in circular RNAs and their role in glioma (Review). Zhang Y; Lin X; Geng X; Shi L; Li Q; Liu F; Fang C; Wang H Int J Oncol; 2020 Jul; 57(1):67-79. PubMed ID: 32319596 [TBL] [Abstract][Full Text] [Related]
25. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Lopci E; Riva M; Olivari L; Raneri F; Soffietti R; Piccardo A; Bizzi A; Navarria P; Ascolese AM; Rudà R; Fernandes B; Pessina F; Grimaldi M; Simonelli M; Rossi M; Alfieri T; Zucali PA; Scorsetti M; Bello L; Chiti A Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1155-1164. PubMed ID: 28110346 [TBL] [Abstract][Full Text] [Related]
26. Liquid biopsies in patients with diffuse glioma. Best MG; Sol N; Zijl S; Reijneveld JC; Wesseling P; Wurdinger T Acta Neuropathol; 2015 Jun; 129(6):849-65. PubMed ID: 25720744 [TBL] [Abstract][Full Text] [Related]
27. Molecular profiling of gliomas--time for a regional service. Hannan C; Al-Rashid S; Herron B; Conkey D; Harney J; Lyness J; Moss J; Flannery T Ulster Med J; 2014 May; 83(2):120-1. PubMed ID: 25075145 [No Abstract] [Full Text] [Related]
28. Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review. Choppavarapu L; Kandi SM Endocr Metab Immune Disord Drug Targets; 2021; 21(2):195-202. PubMed ID: 32744979 [TBL] [Abstract][Full Text] [Related]
29. Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. Waerzeggers Y; Ullrich RT; Monfared P; Viel T; Weckesser M; Stummer W; Schober O; Winkeler A; Jacobs AH Br J Radiol; 2011 Dec; 84 Spec No 2(Spec Iss 2):S179-95. PubMed ID: 22433828 [TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas. Shen F; Zhang Y; Yao Y; Hua W; Zhang HS; Wu JS; Zhong P; Zhou LF Neurosurg Rev; 2014 Jul; 37(3):367-80; discussion 380. PubMed ID: 24781189 [TBL] [Abstract][Full Text] [Related]
31. Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma. Li B; Wang Y; Li S; He H; Sun F; Wang C; Lu Y; Wang X; Tao B Int J Clin Exp Pathol; 2015; 8(6):7016-21. PubMed ID: 26261592 [TBL] [Abstract][Full Text] [Related]
32. Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. Uehara K; Sasayama T; Miyawaki D; Nishimura H; Yoshida K; Okamoto Y; Mukumoto N; Akasaka H; Nishihara M; Fujii O; Soejima T; Sugimura K; Kohmura E; Sasaki R Radiat Oncol; 2012 Jun; 7():104. PubMed ID: 22734595 [TBL] [Abstract][Full Text] [Related]
33. Blood-based biomarkers for the diagnosis and monitoring of gliomas. Zachariah MA; Oliveira-Costa JP; Carter BS; Stott SL; Nahed BV Neuro Oncol; 2018 Aug; 20(9):1155-1161. PubMed ID: 29746665 [TBL] [Abstract][Full Text] [Related]
34. The potential diagnostic and prognostic role of extracellular vesicles in glioma: current status and future perspectives. Azam Z; Quillien V; Wang G; To ST Acta Oncol; 2019 Mar; 58(3):353-362. PubMed ID: 30632857 [TBL] [Abstract][Full Text] [Related]
35. WBSCR22 confers cell survival and predicts poor prognosis in glioma. Chi Y; Liang Z; Guo Y; Chen D; Lu L; Lin J; Qiu S; Wang X; Qiu E; Lin F; Chen J; Luo S; Zheng D; Xu X Brain Res Bull; 2020 Aug; 161():1-12. PubMed ID: 32380188 [TBL] [Abstract][Full Text] [Related]
36. Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Wen PY; Reardon DA Nat Rev Neurol; 2016 Feb; 12(2):69-70. PubMed ID: 26782337 [No Abstract] [Full Text] [Related]
37. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Kalinina J; Peng J; Ritchie JC; Van Meir EG Neuro Oncol; 2011 Sep; 13(9):926-42. PubMed ID: 21852429 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and Prognostic Roles of STAT3 and Its Phosphorylation in Glioma. Liang B; Li SY; Gong HZ; Wang LX; Lu J; Zhao YX; Gu N Dis Markers; 2020; 2020():8833885. PubMed ID: 33299498 [TBL] [Abstract][Full Text] [Related]
40. Expression of CD44 and the survival in glioma: a meta-analysis. Wu G; Song X; Liu J; Li S; Gao W; Qiu M; Yang C; Ma Y; Chen Y Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32232385 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]